FN2 Earnings Intelligence
Bristol-Myers Squibb Company earnings overview
Latest Bristol-Myers Squibb Company (BMY) earnings intelligence, including the newest scorecard, market reaction, and transcript analysis.
Bristol-Myers Squibb Company
Bristol Myers Squibb’s Q2 results support a constructive view of its growth trajectory: the growth portfolio expanded strongly, full-year guidance was raised, and several pipeline programs are advancing. The thesis remains dependent on clinical, regulatory, and launch execution as legacy products face erosion.
Bristol-Myers Squibb Company
Bristol-Myers Squibb posted a convincing Q1 2026 beat, with EPS of $1.58 (vs. $1.42 consensus, +11.3%) and revenue of $11.5B (vs. $10.9B consensus, +5.1%). Growth was anchored by double-digit expansion in early-life-cycle oncology assets Breyanzi and Opdualag, while the pipeline delivered tangible milestones: FDA breakthrough therapy designation for iberdomide (PDUFA August 17), positive Phase III interim data for an ADC in triple-negative breast cancer, and advancing late-stage readouts for Milvexian and oral CELMoDs. Management reaffirmed full-year guidance at the upper end of the range, backed by AI-driven R&D cycle-time reductions and disciplined capital allocation. The stock gained 5.2% on the report but has since drifted roughly 5.6% lower, and at $63.60 trades nearly in line with the $63.25 consensus target, suggesting the market is waiting for pipeline catalysts to materialize…
Bristol-Myers Squibb Company
The supplied analysis supports a constructive but conditional view: growth brands, cost discipline and business development strengthen the near-term narrative, while pipeline execution, Cobenfy adoption and policy pressure remain material tests.
Bristol-Myers Squibb Company
The supplied analysis supports a constructive near-term operating picture: growth-portfolio momentum, raised guidance and pipeline progress provide evidence of resilience. The longer-term case remains conditional on clinical execution, reimbursement and adoption, competitive outcomes, and the pace of legacy-product decline.
Bristol-Myers Squibb Company
The supplied analysis supports a constructive but qualified view: strong growth-portfolio performance, new-product momentum, and raised full-year guidance improve the near-term outlook, while trial execution, legacy-portfolio pressure, tariffs, and pipeline competition remain material risks.
Bristol-Myers Squibb Company
The supplied Q2 analysis supports a constructive but conditional thesis: growth-portfolio momentum, new launches, pipeline progress and cost efficiencies improved the outlook, while pricing, competition and execution risks remain material.
Bristol-Myers Squibb Company
Bristol-Myers Squibb's Q1 update supports a transition thesis: growth products and pipeline progress are expanding while cost savings are intended to fund further investment. The evidence is constructive, but the thesis remains dependent on execution against launches and trials while the company manages IRA pricing, patent and competitive pressures.
Get the BMY recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.